Russia successfully develops vaccine for colorectal cancer

STC NEWS MONITORING DESK
MOSCOW, SEPTEMBER 06 (STC): Here is a reason for cancer patients to smile! According to Tass.com, Russia’s cancer vaccine has successfully completed preclinical trials. The trials have demonstrated both safety and high efficacy, says the Tass report quoting Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA). The success of the preclinical trials of the cancer vaccine were announced by the FMBA head at the Eastern Economic Forum (EEF).
The vaccine is now ready for use and official approval id awaited, said the report.
As per the Tass report, quoting the FMBA head, preclinical results confirmed the vaccine’s safety, even with repeated administration, and its significant effectiveness. Researchers observed reductions in tumor size and slowed tumor progression – ranging from 60% to 80% – depending on the disease characteristics. Additionally, studies indicated increased survival rates attributable to the vaccine.
Notably, the initial target for this vaccine will be colorectal cancer. Moreover, promising progress has been made in developing vaccines for glioblastoma and specific types of melanoma, including ocular melanoma, which are currently at advanced stages of development, reads the report.
(Straight Talk Communications)